Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 403

1.
2.

Clinical and cost outcomes of pre-emptive plerixafor administration in patients with multiple myeloma undergoing stem cell mobilization.

Andritsos LA, Huang Y, Abraham I, Huff K, Scrape SR, Fan T, Alkhatib N, Hofmeister CC, Drea E, McBride A.

Leuk Res. 2019 Oct;85:106215. doi: 10.1016/j.leukres.2019.106215. Epub 2019 Aug 9.

PMID:
31470355
3.

Cost-effectiveness model of abiraterone plus prednisone, cabazitaxel plus prednisone and enzalutamide for visceral metastatic castration resistant prostate cancer therapy after docetaxel therapy resistance.

Barqawi YK, Borrego ME, Roberts MH, Abraham I.

J Med Econ. 2019 Nov;22(11):1202-1209. doi: 10.1080/13696998.2019.1661581. Epub 2019 Sep 17.

PMID:
31452414
4.

Febrile neutropenia hospitalization due to pegfilgrastim on-body injector failure compared to single-injection pegfilgrastim and daily injections with reference and biosimilar filgrastim: US cost simulation for lung cancer and non-Hodgkin lymphoma.

McBride A, Krendyukov A, Mathieson N, Campbell K, Balu S, Natek M, MacDonald K, Abraham I.

J Med Econ. 2019 Sep 3:1-9. doi: 10.1080/13696998.2019.1658591. [Epub ahead of print]

PMID:
31433700
5.

Response to Yang, Shi, Wang, et al.

Oh M, McBride A, Yun S, Bhattacharjee S, Slack M, Martin JR, Jeter J, Abraham I.

J Natl Cancer Inst. 2019 Aug 19. pii: djz163. doi: 10.1093/jnci/djz163. [Epub ahead of print] No abstract available.

PMID:
31424546
6.

Physicians' perceptions, expectations, and experiences of clinical pharmacists in Jordan-2017.

Tahaineh L, Wazaify M, Alomoush F, Nasser SA, Alrawashdh N, Abraham I.

Int J Clin Pharm. 2019 Oct;41(5):1193-1201. doi: 10.1007/s11096-019-00884-6. Epub 2019 Aug 3.

PMID:
31377967
7.

Prognostic significance of MYC oncoprotein expression on survival outcome in patients with acute myeloid leukemia with myelodysplasia related changes (AML-MRC).

Yun S, Sharma R, Chan O, Vincelette ND, Sallman DA, Sweet K, Padron E, Komrokji R, Lancet JE, Abraham I, Moscinski LC, Cleveland JL, List AF, Zhang L.

Leuk Res. 2019 Sep;84:106194. doi: 10.1016/j.leukres.2019.106194. Epub 2019 Jul 18.

PMID:
31357093
8.

Real-World Evidence from the Integrative Medicine Primary Care Trial (IMPACT): Assessing Patient-Reported Outcomes at Baseline and 12-Month Follow-Up.

Crocker RL, Hurwitz JT, Grizzle AJ, Abraham I, Rehfeld R, Horwitz R, Weil AT, Maizes V.

Evid Based Complement Alternat Med. 2019 Jun 26;2019:8595409. doi: 10.1155/2019/8595409. eCollection 2019.

9.

Comparative efficacy and safety of immunotherapies targeting the PD-1/PD-L1 pathway for previously treated advanced non-small cell lung cancer: A Bayesian network meta-analysis.

Almutairi AR, Alkhatib N, Martin J, Babiker HM, Garland LL, McBride A, Abraham I.

Crit Rev Oncol Hematol. 2019 Oct;142:16-25. doi: 10.1016/j.critrevonc.2019.07.004. Epub 2019 Jul 10.

PMID:
31326706
10.

Why health policies should be transnational: A case for East Asia Pacific countries.

Ambade PN, Katragadda C, Sun D, Bootman JL, Abraham I.

Int J Risk Saf Med. 2019;30(2):101-125. doi: 10.3233/JRS-199001.

PMID:
31282430
11.

Center-Specific Modeling Predicts Cancer Trial Accrual More Accurately Than Investigators and Random Effects Modeling at 16 Cancer Centers.

Tate WR, Abraham I, Cranmer LD.

JCO Clin Cancer Inform. 2019 Jun;3:1-12. doi: 10.1200/CCI.19.00005.

12.

The Importance of Outcome and Precise Evaluation in Economic Analysis of Cancer Drugs-Reply.

Almutairi AR, Alkhatib NS, Abraham I.

JAMA Dermatol. 2019 Jul 1;155(7):863. doi: 10.1001/jamadermatol.2019.0135. No abstract available.

PMID:
31066865
13.

Comparing incomparables with the wrong analytics: Anticoagulation, disability, intracranial hemorrhage, and mortality in acute cerebral vein thrombosis.

Almulhim AS, Fallatah S, Abraham I.

Thromb Res. 2019 Jun;178:110-111. doi: 10.1016/j.thromres.2019.04.009. Epub 2019 Apr 12.

PMID:
31005666
14.

Variability in total serum IgE over 1 year in severe asthmatics.

Louis R, Pilette C, Michel O, Michils A, Brusselle G, Poskin A, Van Schoor J, Denhaerynck K, Vancayzeele S, Abraham I, Gurdain S.

Allergy Asthma Clin Immunol. 2019 Mar 29;15:20. doi: 10.1186/s13223-019-0331-8. eCollection 2019.

15.

Effectiveness and Tolerability of Vildagliptin and the Single Pill Combination of Vildagliptin and Metformin in "Real-World" Management of Type 2 Diabetes Mellitus: The G-FORCE Study.

Van Gaal L, Hermans MP, Daci E, Denhaerynck K, De Meester L, MacDonald K, Abraham I, Vancayzeele S, Maris M.

Diabetes Ther. 2019 Jun;10(3):965-979. doi: 10.1007/s13300-019-0601-y. Epub 2019 Mar 27.

16.

The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta-analysis.

Oh M, Alkhushaym N, Fallatah S, Althagafi A, Aljadeed R, Alsowaida Y, Jeter J, Martin JR, Babiker HM, McBride A, Abraham I.

Prostate. 2019 Jun;79(8):880-895. doi: 10.1002/pros.23795. Epub 2019 Mar 22.

PMID:
30900310
17.

Potential life-years gained over a 5-year period by correcting DOPPS-identified modifiable practices in haemodialysis: results from the European MONITOR-CKD5 study.

Combe C, Mann J, Goldsmith D, Dellanna F, Zaoui P, London G, Denhaerynck K, Krendyukov A, Abraham I, MacDonald K.

BMC Nephrol. 2019 Mar 5;20(1):81. doi: 10.1186/s12882-019-1251-z.

18.

Chemotherapy-induced neutropenia/febrile neutropenia prophylaxis with biosimilar filgrastim in solid tumors versus hematological malignancies: MONITOR-GCSF study.

Ludwig H, Bokemeyer C, Aapro M, Boccadoro M, Gascón P, Denhaerynck K, Krendyukov A, Abraham I, MacDonald K.

Future Oncol. 2019 Mar;15(8):897-907. doi: 10.2217/fon-2018-0814. Epub 2019 Mar 4.

19.

Dissociating tinnitus patients from healthy controls using resting-state cyclicity analysis and clustering.

Zimmerman BJ, Abraham I, Schmidt SA, Baryshnikov Y, Husain FT.

Netw Neurosci. 2018 Oct 1;3(1):67-89. doi: 10.1162/netn_a_00053. eCollection 2019.

20.

[The continuum hypothesis of eating disorders, the evolution of a model from 1970's to the present].

Abraham I.

Neuropsychopharmacol Hung. 2018 Dec;20(4):131-139. Hungarian.

21.

Short- and long-term real-world effectiveness of omalizumab in severe allergic asthma: systematic review of 42 studies published 2008-2018.

MacDonald KM, Kavati A, Ortiz B, Alhossan A, Lee CS, Abraham I.

Expert Rev Clin Immunol. 2019 May;15(5):553-569. doi: 10.1080/1744666X.2019.1574571. Epub 2019 Feb 14.

PMID:
30763137
22.

Comprehensive Lifestyle Improvement Program for Prostate Cancer (CLIPP): Protocol for a Feasibility and Exploratory Efficacy Study in Men on Androgen Deprivation Therapy.

Algotar A, Hsu CH, Sherry Chow HH, Dougherty S, Babiker HM, Marrero D, Abraham I, Kumar R, Ligibel J, Courneya KS, Thomson C.

JMIR Res Protoc. 2019 Feb 5;8(2):e12579. doi: 10.2196/12579.

23.

Response to Katona et al.

Oh M, McBride A, Yun S, Bhattacharjee S, Slack M, Martin JR, Jeter J, Abraham I.

J Natl Cancer Inst. 2019 May 1;111(5):524-525. doi: 10.1093/jnci/djz013. No abstract available.

PMID:
30715401
24.

A Cautionary Research Note on Standard Versus Extended Release Tacrolimus.

Abraham I, Alsheikh R, MacDonald K.

Prog Transplant. 2018 Dec 5:1526924818817070. doi: 10.1177/1526924818817070. [Epub ahead of print] No abstract available.

PMID:
30518291
25.

Correction to: Direct oral anticoagulants for the treatment of venous thromboembolism in patients with active malignancy: a systematic review and meta-analysis.

Al Yami MS, McBride A, Katragadda C, Martin JR, Badreldin HA, Mohammed AH, Elmubark AM, Alzahrani MY, Alsheri AM, Abraham I.

J Thromb Thrombolysis. 2019 Jan;47(1):166. doi: 10.1007/s11239-018-1777-0.

PMID:
30478721
26.

Economic Evaluation of Talimogene Laherparepvec Plus Ipilimumab Combination Therapy vs Ipilimumab Monotherapy in Patients With Advanced Unresectable Melanoma.

Almutairi AR, Alkhatib NS, Oh M, Curiel-Lewandrowski C, Babiker HM, Cranmer LD, McBride A, Abraham I.

JAMA Dermatol. 2019 Jan 1;155(1):22-28. doi: 10.1001/jamadermatol.2018.3958.

27.

Benefits and Harms of Omalizumab Treatment in Adolescent and Adult Patients With Chronic Idiopathic (Spontaneous) Urticaria: A Meta-analysis of "Real-world" Evidence.

Tharp MD, Bernstein JA, Kavati A, Ortiz B, MacDonald K, Denhaerynck K, Abraham I, Lee CS.

JAMA Dermatol. 2019 Jan 1;155(1):29-38. doi: 10.1001/jamadermatol.2018.3447. Review.

28.

Staging Systems to Predict Metastatic Cutaneous Squamous Cell Carcinoma: Unsatisfactory for Clinical Use, but Some Less So?

Abraham I, Curiel-Lewandrowski C.

JAMA Dermatol. 2018 Dec 1;154(12):1391-1392. doi: 10.1001/jamadermatol.2018.3940. No abstract available.

PMID:
30419110
29.

The Role of Interleukin-10 in Mediating the Effect of Immune Challenge on Mouse Gonadotropin-Releasing Hormone Neurons In Vivo.

Barabás K, Barad Z, Dénes Á, Bhattarai JP, Han SK, Kiss E, Sármay G, Ábrahám IM.

eNeuro. 2018 Oct 15;5(5). pii: ENEURO.0211-18.2018. doi: 10.1523/ENEURO.0211-18.2018. eCollection 2018 Sep-Oct.

30.

BRCA1 and BRCA2 Gene Mutations and Colorectal Cancer Risk: Systematic Review and Meta-analysis.

Oh M, McBride A, Yun S, Bhattacharjee S, Slack M, Martin JR, Jeter J, Abraham I.

J Natl Cancer Inst. 2018 Nov 1;110(11):1178-1189. doi: 10.1093/jnci/djy148.

PMID:
30380096
31.

Outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (Zarzio®) initiated "same-day" (< 24 h), "per-guidelines" (24-72 h), and "late" (> 72 h): findings from the MONITOR-GCSF study.

Ludwig H, Gascón P, Bokemeyer C, Aapro M, Boccadoro M, Denhaerynck K, Krendyukov A, MacDonald K, Abraham I.

Support Care Cancer. 2019 Jun;27(6):2301-2312. doi: 10.1007/s00520-018-4513-6. Epub 2018 Oct 20.

PMID:
30343410
32.

A feasibility study of breast cancer genetic risk assessment in a federally qualified health center.

Hoskins KF, Tejeda S, Vijayasiri G, Chukwudozie IB, Remo MH, Shah HA, Abraham IE, Balay LE, Maga TK, Searles ER, Korah VJ, Biggers A, Stolley MR, Warnecke RB.

Cancer. 2018 Sep 15;124(18):3733-3741. doi: 10.1002/cncr.31635. Epub 2018 Oct 15.

33.

Economic evaluation of a pharmacogenomic multi-gene panel test to optimize anti-hypertension therapy: simulation study.

Kelley EF, Snyder EM, Alkhatib NS, Snyder SC, Sprissler R, Olson TP, Akre MK, Abraham I.

J Med Econ. 2018 Dec;21(12):1246-1253. doi: 10.1080/13696998.2018.1531011. Epub 2018 Oct 22.

PMID:
30280614
34.

A single-arm, retrospective analysis of the incidence of febrile neutropenia using same-day versus next-day pegfilgrastim in patients with gastrointestinal cancers treated with FOLFOX or FOLFIRI.

Eckstrom J, Bartels T, Abraham I, Patel H, Elquza E, Scott AJ, Malangone S, Hollings J, McBride A.

Support Care Cancer. 2019 Mar;27(3):873-878. doi: 10.1007/s00520-018-4373-0. Epub 2018 Aug 8.

PMID:
30090991
35.

The case for rejecting the memristor as a fundamental circuit element.

Abraham I.

Sci Rep. 2018 Jul 20;8(1):10972. doi: 10.1038/s41598-018-29394-7.

36.

Economic Evaluation for the UK of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer.

Gharaibeh M, McBride A, Alberts DS, Erstad B, Slack M, Alsaid N, Bootman JL, Abraham I.

Pharmacoeconomics. 2018 Nov;36(11):1333-1343. doi: 10.1007/s40273-018-0684-8.

PMID:
29981004
37.

Efficacy and Safety of Sorafenib in a Racially Diverse Patient Population with Advanced Hepatocellular Carcinoma.

Schmidt TM, Liu LI, Abraham IE, Uy AB, Dudek AZ.

Anticancer Res. 2018 Jul;38(7):4027-4034. doi: 10.21873/anticanres.12691.

PMID:
29970527
38.

Economic Evaluation for USA of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer.

Gharaibeh M, McBride A, Alberts DS, Slack M, Erstad B, Alsaid N, Bootman JL, Abraham I.

Pharmacoeconomics. 2018 Oct;36(10):1273-1284. doi: 10.1007/s40273-018-0678-6.

PMID:
29948964
39.

Rapid non-classical effects of steroids on the membrane receptor dynamics and downstream signaling in neurons.

Barabás K, Godó S, Lengyel F, Ernszt D, Pál J, Ábrahám IM.

Horm Behav. 2018 Aug;104:183-191. doi: 10.1016/j.yhbeh.2018.05.008. Epub 2018 May 19. Review.

PMID:
29775570
40.

Efficacy and toxicity profile of carfilzomib based regimens for treatment of multiple myeloma: A systematic review.

Mushtaq A, Kapoor V, Latif A, Iftikhar A, Zahid U, McBride A, Abraham I, Riaz IB, Anwer F.

Crit Rev Oncol Hematol. 2018 May;125:1-11. doi: 10.1016/j.critrevonc.2018.02.008. Epub 2018 Mar 2. Review.

41.

Reply: Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia.

McBride A, Campbell K, Bikkina M, MacDonald K, Abraham I, Balu S.

J Med Econ. 2018 Jun;21(6):606-609. doi: 10.1080/13696998.2018.1452749. Epub 2018 Apr 12. No abstract available.

PMID:
29561198
42.

Direct oral anticoagulants for extended thromboprophylaxis in medically ill patients: meta-analysis and risk/benefit assessment.

Al Yami MS, Kurdi S, Abraham I.

J Blood Med. 2018 Feb 21;9:25-34. doi: 10.2147/JBM.S149202. eCollection 2018.

43.

Effectiveness of omalizumab in adolescent and adult patients with chronic idiopathic/spontaneous urticaria: a systematic review of 'real-world' evidence.

Bernstein JA, Kavati A, Tharp MD, Ortiz B, MacDonald K, Denhaerynck K, Abraham I.

Expert Opin Biol Ther. 2018 Apr;18(4):425-448. doi: 10.1080/14712598.2018.1438406. Epub 2018 Feb 16.

PMID:
29431518
44.

Letter to the Editor: When Claiming a U-shaped Association between Uric Acid Levels and Major Adverse Cardiac Events, Perhaps Show the Evidence?

Abraham I.

J Korean Med Sci. 2018 Feb 5;33(6):e50. doi: 10.3346/jkms.2018.33.e50. No abstract available.

45.

Long-term treatment with biosimilar epoetin-α (HX575) in hemodialysis patients with renal anemia: real-world effectiveness and safety in the MONITOR-CKD5 study
.

London G, Mann J, Goldsmith D, Combe C, Dellanna F, Zaoui P, Hoebel N, Krendyukov A, MacDonald K, Abraham I.

Clin Nephrol. 2018 Jan;89 (2018)(1):1-9. doi: 10.5414/CN109245.

46.

Hierarchical Modeling of Patient and Physician Determinants of Blood Pressure Outcomes in Hypertensive Patients with and without Diabetes: Pooled Analysis of Six Observational Valsartan Studies with 15,282 Evaluable Patients.

Ashy N, Nguyen TN, Denhaerynck K, Gharaibeh M, Alhossan A, Vancayzeele S, Brié H, Aerts A, MacDonald K, Abraham I.

Int J Chronic Dis. 2017;2017:9842450. doi: 10.1155/2017/9842450. Epub 2017 Sep 25.

47.

Integrative medicine primary care: assessing the practice model through patients' experiences.

Crocker RL, Grizzle AJ, Hurwitz JT, Rehfeld RA, Abraham I, Horwitz R, Weil A, Maizes V.

BMC Complement Altern Med. 2017 Nov 15;17(1):490. doi: 10.1186/s12906-017-1996-5.

48.

Adherence to fingolimod in multiple sclerosis: an investigator-initiated, prospective, observational, single-center cohort study.

Zimmer A, Coslovsky M, Abraham I, Décard BF.

Patient Prefer Adherence. 2017 Oct 20;11:1815-1830. doi: 10.2147/PPA.S140293. eCollection 2017.

49.

Dynamic changes in binding interaction networks of sex steroids establish their non-classical effects.

Bálint M, Jeszenői N, Horváth I, Ábrahám IM, Hetényi C.

Sci Rep. 2017 Nov 1;7(1):14847. doi: 10.1038/s41598-017-14840-9.

50.

Estradiol Sensitizes the Transient Receptor Potential Vanilloid 1 Receptor in Pain Responses.

Payrits M, Sághy É, Cseko K, Pohóczky K, Bölcskei K, Ernszt D, Barabás K, Szolcsányi J, Ábrahám IM, Helyes Z, Szoke É.

Endocrinology. 2017 Oct 1;158(10):3249-3258. doi: 10.1210/en.2017-00101.

PMID:
28977586

Supplemental Content

Loading ...
Support Center